Table 1.

Study patient characteristics and treatment outcomes in detail for the infused patients, N=14.

Acc #	Age	Gender	Diagnosis	Prior lines of therapy	Prior transplant	Cohort	CRS	ICANS	Response	Progressed	Status at last follow-up
2	68	M	CLL	3	No	1	No	No	No response	Yes	Died, secondary cancer
4	40	M	ALL	6	Yes	1	No	No	CRi	Yes	Died, active disease
6	36	F	DLBCL	4	Yes	-1	No	No	No response	Yes	Died, active disease
8	40	F	ALL	4	Yes	1	No	No	CR	Yes	Died, active disease
9	29	F	ALL	4	No	2	Yes	No	No response	Yes	Died, active disease
13	46	M	ALL	5	Yes	2	Yes	No	MRD negative	Yes	Died, active disease
14	72	M	DLBCL	5	Yes	2	Yes	No	CR	No	Alive, in remission
16	16	M	ALL	3	Yes	1	No	No	No response	Yes	Died, active disease
20	47	F	DLBCL*	3	No	3	No	No	CR	Yes	Alive, in remission
21	31	M	ALL	4	Yes	3	No	No	No response	Yes	Died, active disease
22	73	F	DLBCL	2	No	-1	No	No	Progression	Yes	Died, active disease
23	57	F	CLL	3	Yes	3	No	No	No response	Yes	Alive, active disease
25	34	M	ALL	4	Yes	1	No	No	No response	Yes	Died, active disease
26	39	M	ALL	2	Yes	1	No	No	MRD positive	No	Alive, in remission

ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CR, complete remission; CRi, CR with incomplete platelet and/or neutrophil recovery; CRS, cytokine release syndrome; ICANS, immune effector cell associated neurotoxicity syndrome; DLBCL, diffuse large B-cell lymphoma; F, female; M, male; MRD, minimal residual disease.

*Transformed from marginal zone lymphoma.